<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05112445</url>
  </required_header>
  <id_info>
    <org_study_id>4C-2021-10</org_study_id>
    <nct_id>NCT05112445</nct_id>
  </id_info>
  <brief_title>Retinal Ischemia Characterization in Diabetes - &quot;RICHARD&quot;</brief_title>
  <acronym>RICHARD</acronym>
  <official_title>Retinal Ischemia Characterization in Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association for Innovation and Biomedical Research on Light and Image</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Association for Innovation and Biomedical Research on Light and Image</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retinal ischemia characterization in diabetes - RICHARD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RICHARD is a non-interventional observational cross-sectional and prospective study. Patients&#xD;
      will attend their routine clinical appointments, with 2-years of follow-up. Type 2 diabetic&#xD;
      individuals with retinopathy ETDRS DRSS grade 43 with IRMA or grade 47-53 will be recruited&#xD;
      and examined using non-invasive methodologies.&#xD;
&#xD;
      The study will be performed at AIBILI Clinical Trials Centre (CEC). Demographic and systemic&#xD;
      parameters, such as diabetes duration, medical history, medication, body mass index, and&#xD;
      family history of medical conditions (particularly when related to cognitive decline) will be&#xD;
      registered at baseline.&#xD;
&#xD;
      All subjects will undergo an annual complete non-invasive ophthalmological examination, which&#xD;
      includes, best corrected visual acuity, 7-fields CFP to assess ETDRS DRSS level, structural&#xD;
      SD-OCT, SD-OCTA, SS-OCTA and ultra-widefield fundus photography (UWF FP). An invasive&#xD;
      ophthalmological examination, the Ultra-wide field fundus fluorescein angiography (UWF FFA)&#xD;
      will be obtained from both eyes at baseline (V0, M0) only in subjects with ETDRS DRSS grade&#xD;
      43 for final eligibility (43+IRMA).&#xD;
&#xD;
      Ophthalmological examinations performed will be analyzed at AIBILI Coimbra Ophthalmology&#xD;
      Reading Centre (CORC) and Centre for New Technologies e Medicine (CNTM).&#xD;
&#xD;
      Color fundus photography (7-fields) will be acquired at V0 (month 0, baseline,&#xD;
      cross-sectional study), V2 (month 12) and V3 (month 24), and then graded and classified&#xD;
      according to the ETDRS severity scale by CORC, to allow evaluation of retinopathy progression&#xD;
      over two years of follow-up. . At baseline visit (V0) both eyes will be evaluated and the&#xD;
      study eye will be selected according to ETDRS DRSS grade (43 with IRMA, 47 or 53). Only the&#xD;
      study eye will be considered for the primary statistical analysis; other statistical analyses&#xD;
      will include both eyes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2022</start_date>
  <completion_date type="Anticipated">August 14, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>OCTA metrics and predict progression to PDR and/ or CI- DME</measure>
    <time_frame>Change from baseline to Month 12</time_frame>
    <description>Identify which baseline OCTA metrics and predict progression to PDR and/ or CI- DME best correlate with visual function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OCTA metrics and predict progression to PDR and/ or CI- DME</measure>
    <time_frame>Change from baseline to Month 24</time_frame>
    <description>Identify which baseline OCTA metrics and predict progression to PDR and/ or CI- DME best correlate with visual function.</description>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        60 individuals with type 2 diabetes and diabetic retinopathy with ETDRS DRSS grade 43 with&#xD;
        IRMA, 47 or 53, with or without previous treatment, will be included in this study, over a&#xD;
        recruitment period of 6 months.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diabetes type 2 according to 1985 WHO definition.&#xD;
&#xD;
          -  Age over 18 years old.&#xD;
&#xD;
          -  NPDR levels ETDRS DRSS (43 with IRMA, 47 or 53), based on the ETDRS criteria - 7&#xD;
             fields CFP and UWF FFA for 43 with IRMA after confirmation by the Reading Centre&#xD;
             (CORC).&#xD;
&#xD;
          -  Refraction with a spherical equivalent less than 5 diopters&#xD;
&#xD;
          -  Able to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of diabetic macular edema (DME) involving the center of the macula in the&#xD;
             study eye and needing immediate treatment.&#xD;
&#xD;
          -  Presence of CI-DME defined as central subfield thickness on OCT ≥305 µm if male or&#xD;
             ≥290 µm if female on Zeiss Cirrus OCT [12] with vision loss and needing immediate&#xD;
             treatment.&#xD;
&#xD;
          -  Cataract or other eye disease that may interfere with fundus examinations or OCT/OCTA&#xD;
             signal strength.&#xD;
&#xD;
          -  Age-related macular degeneration, glaucoma, vitreomacular disease, other retinal&#xD;
             vascular disease, or any ocular condition that, in the opinion of the investigator may&#xD;
             affect retinopathy status or alter VA during the study.&#xD;
&#xD;
          -  Any eye surgery, including laser, and anti-VEGF within a period of 6-months.&#xD;
&#xD;
          -  Dilatation of the pupil &gt; 5 mm.&#xD;
&#xD;
          -  HbA1c &gt; 12% in the last measurement prior to the study visit (V0). Study Eye: Only one&#xD;
             eye per subject will be considered for the primary statistical analysis (Study Eye).&#xD;
             If both eyes meet the inclusion criteria the study eye will be the one that has a&#xD;
             higher level of DR (ETDRS classification). If both eyes have the same ETDRS DRSS&#xD;
             grading, the eye with higher BCVA will be chosen. If both eyes have the same BCVA, the&#xD;
             right eye will be chosen.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ana M Ferreira, MsC</last_name>
    <phone>+351 239 480 137</phone>
    <email>amfernandes@aibili.pt</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liliana C Soares, MsC</last_name>
    <phone>+351 239 480 112</phone>
    <email>lcarvalho@aibili.pt</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AIBILI-CEC (AIBILI- Clinical Trials Centre)</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-548</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Inês P Marques, PhD MD</last_name>
      <phone>+351 239 480 124</phone>
      <email>ipmarques@aibili.pt</email>
    </contact>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

